ADMP
Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corp
$ADMP reports FY2022 results & merger agreement with DMK Pharmaceuticals
Adamis Pharmaceuticals Corp. released its financial results for the year ending Dec 31, 2022, with a net loss of $28.2M or $(0.24) per share. The biopharmaceutical company is set to merge with DMK Pharmaceuticals, pending stockholder's approval. Nasdaq extended Adamis' compliance period to regain compliance with a $1 minimum bid share price requirement. However, the company stated that it may become bankrupt if it doesn't receive required funding, putting the stockholders' investment at risk. Adamis' FDA-approved products include ZIMHI® Injection and SYMJEPI® Injection. The CEO focuses on executing the merger with DMK Pharmaceuticals to drive the firm's growth.
9d ago
$ADMP